## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.2% below STRENGTH zone (4.0-10.0%); PEG 35.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($17.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 10)

**1. Shareholders SueWallSt in New Class Action Against Baxter International, Inc. - Act Now**
- Source: Fox 59 | 20251203T221500 | Bearish | Relevance: 100%
- A class action lawsuit has been filed against Baxter International, Inc., on behalf of investors who allegedly suffered losses due to securities fraud between February 23, 2022, and July 30, 2025. Levi & Korsinsky is representing the aggrieved shareholders and encourages affected investors to contact them for more information. The firm specializes in complex securities litigation and has a history of winning high-stakes cases.

**2. BAXTER INTERNATIONAL INC. (NYSE: BAX) SHAREHOLDER ALERT**
- Source: GlobeNewswire | 20251203T171500 | Bearish | Relevance: 100%
- Bernstein Liebhard LLP reminds investors of an upcoming deadline for a class action lawsuit against Baxter International Inc. The lawsuit alleges securities fraud, claiming Baxter misrepresented the safety of its Novum IQ Large Volume Pump between February 23, 2022, and July 30, 2025. Investors who purchased shares during this period and suffered losses are encouraged to contact the firm by December 15, 2025, to discuss their options or serve as lead plaintiff.

**3. The Gross Law Firm Notifies Baxter International, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline â€“ BAX**
- Source: EverythingLubbock.com | 20251203T162200 | Bearish | Relevance: 100%
- The Gross Law Firm has announced a class action lawsuit against Baxter International, Inc. (NYSE: BAX) for investors who purchased shares between February 23, 2022, and July 30, 2025. The lawsuit alleges that Baxter made misleading statements regarding its Novum LVP product, which reportedly suffered from systemic defects leading to malfunctions, patient injuries, and deaths. Shareholders are encouraged to contact the law firm by the December 15, 2025 deadline to seek lead plaintiff appointment.

**4. BAX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!**
- Source: Fox 59 | 20251203T070000 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Baxter International, Inc. (NYSE:BAX) on behalf of investors who purchased securities between February 23, 2023, and July 30, 2025. The lawsuit alleges that Baxter misled investors regarding systemic defects in its Novum LVP product, which caused malfunctions leading to patient injury or death. Investors with losses have until December 15, 2025, to request appointment as lead plaintiff.

**5. BAX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Baxter International, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!**
- Source: WJBF | 20251203T070000 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Baxter International, Inc. (NYSE:BAX) on behalf of investors who suffered losses between February 23, 2023, and July 30, 2025. The lawsuit alleges that Baxter misled investors regarding systemic defects in its Novum LVP product, leading to patient risks and inadequate remedial measures. Investors with losses have until December 15, 2025, to request to be appointed as lead plaintiff.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.17M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.4x requires aggressive growth execution.
2. Elevated short interest (9.8%): bears positioning against stock.
3. Long-term trend broken: trading 30.3% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 35.42 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.42 |
| Forward P/E | 8.2 |
| Current P/E | 8.0 |
| YoY Growth | -2.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.0% to 1.2% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.8pp (needs >4.0% for momentum thesis). MRS_5 (-0.5%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.1% shows strong absolute momentum above own 20MA. Below SMA200 (0.70x), long-term trend not supportive. RSI neutral at 46. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.23% (CS: 64) | Neutral |
| RSI_14 | 46.4 | Neutral |
| MACD Histogram | 0.27 | Bullish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 0.915x | Below |
| vs SMA200 | 0.697x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $18.89
- **Stop Loss:** $17.71 (6.2% risk)
- **Target:** $20.07 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 805
- **Position Value:** $15,206.45
- **Portfolio %:** 15.21%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*